Evaluation of Blood-Based Plasma Biomarkers as Potential Markers of Amyloid Burden in Preclinical Alzheimer's Disease.

Autor:	Winston CN; Department of Neurosciences, University of California San Diego, La Jolla, CA, USA., Langford O; Alzheimer's Therapeutic Research Institute, Keck School of Medicine University of Southern California, San Diego, CA, USA., Levin N; Department of Neurosciences, University of California San Diego, La Jolla, CA, USA., Raman R; Alzheimer's Therapeutic Research Institute, Keck School of Medicine University of Southern California, San Diego, CA, USA., Yarasheski K; C2N Diagnostics, St. Louis, MO, USA., West T; C2N Diagnostics, St. Louis, MO, USA., Abdel-Latif S; Alzheimer's Therapeutic Research Institute, Keck School of Medicine University of Southern California, San Diego, CA, USA., Donohue M; Alzheimer's Therapeutic Research Institute, Keck School of Medicine University of Southern California, San Diego, CA, USA., Nakamura A; Department of Biomarker Research, National Center for Geriatrics and Gerontology, Obu, Aichi, Japan., Toba K; National Center for Geriatrics and Gerontology, Obu, Aichi, Japan.; Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan., Masters CL; The Florey Institute, The University of Melbourne, Parkville, VIC, Australia., Doecke J; The Commonwealth Scientific and Industrial Research Organization, Brisbane, QLD, Australia., Sperling RA; Harvard Medical School, Boston, MA, USA., Aisen PS; Alzheimer's Therapeutic Research Institute, Keck School of Medicine University of Southern California, San Diego, CA, USA., Rissman RA; Department of Neurosciences, University of California San Diego, La Jolla, CA, USA.; Department of Neurosciences, University of California San Diego and VA San Diego Healthcare System, La Jolla, CA, USA.
Jazyk:	angličtina
Zdroj:	Journal of Alzheimer's disease : JAD [J Alzheimers Dis] 2023; Vol. 92 (1), pp. 95-107.
DOI:	10.3233/JAD-221118
Abstrakt:	Background: Participant eligibility for the A4 Study was determined by amyloid PET imaging. Given the disadvantages of amyloid PET imaging in accessibility and cost, blood-based biomarkers may serve as a sufficient biomarker and more cost-effective screening tool for patient enrollment into preclinical AD trials. Objective: To determine if a blood-based screening test can adequately identify amyloid burden in participants screened into a preclinical AD trial. Methods: In this cross-sectional study, 224 participants from the A4 Study received an amyloid PET scan (18Florbetapir) within 90 days of blood sample collection. Blood samples from all study participants were processed within 2 h after phlebotomy. Plasma amyloid measures were quantified by Shimazdu and C2 N Diagnostics using mass spectrometry-based platforms. A corresponding subset of blood samples (n = 100) was processed within 24 h after phlebotomy and analyzed by C2 N. Results: Plasma Aβ42/Aβ40 demonstrated the highest association for Aβ accumulation in the brain with an AUC 0.76 (95%CI = 0.69, 0.82) at C2 N and 0.80 (95%CI = 0.75, 0.86) at Shimadzu. Blood samples processed to plasma within 2 h after phlebotomy provided a better prediction of amyloid PET status than blood samples processed within 24 h (AUC 0.80 versus 0.64; p < 0.001). Age, sex, and APOE ɛ4 carrier status did not the diagnostic performance of plasma Aβ42/Aβ40 to predict amyloid PET positivity in A4 Study participants. Conclusion: Plasma Aβ42/Aβ40 may serve as a potential biomarker for predicting elevated amyloid in the brain. Utilizing blood testing over PET imaging may improve screening efficiency into clinical trials.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu